Literature DB >> 20068404

Ofatumumab.

Bodi Zhang1.   

Abstract

Ofatumumab is an anti-CD20 IgG1kappa human monoclonal antibody that is being considered by the US Food and Drug Administration and the European Medicines Agency for marketing approval as a treatment for chronic lymphocytic leukemia. The mAb is also being studied as a treatment for lymphoma, rheumatoid arthritis and multiple sclerosis. The candidate targets the same antigen as rituximab, but ofatumumab binds a novel, membrane-proximal epitope, and dissociates from its target at a slower rate compared to rituximab. Ofatumumab might be approved in the US by August 2009.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20068404      PMCID： PMC2726602          DOI： 10.4161/mabs.1.4.8895

Source DB:  PubMed          Journal:  MAbs        ISSN： 1942-0862            Impact factor:   5.857


  16 in total

Review 1.  Clinical applications of anti-CD20 antibodies.

Authors:  A K Gopal; O W Press
Journal:  J Lab Clin Med       Date:  1999-11

2.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

Review 3.  Anti-CD20-based therapy of B cell lymphoma: state of the art.

Authors:  C Kosmas; K Stamatopoulos; N Stavroyianni; N Tsavaris; T Papadaki
Journal:  Leukemia       Date:  2002-10       Impact factor: 11.528

4.  Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.

Authors:  M J Leandro; J C W Edwards; G Cambridge
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

5.  The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Authors:  Jessica L Teeling; Wendy J M Mackus; Luus J J M Wiegman; Jeroen H N van den Brakel; Stephen A Beers; Ruth R French; Tom van Meerten; Saskia Ebeling; Tom Vink; Jerry W Slootstra; Paul W H I Parren; Martin J Glennie; Jan G J van de Winkel
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

6.  Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.

Authors:  Paul V Beum; Margaret A Lindorfer; Frank Beurskens; P Todd Stukenberg; Henk M Lokhorst; Andrew W Pawluczkowycz; Paul W H I Parren; Jan G J van de Winkel; Ronald P Taylor
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

7.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

Authors:  M E Reff; K Carner; K S Chambers; P C Chinn; J E Leonard; R Raab; R A Newman; N Hanna; D R Anderson
Journal:  Blood       Date:  1994-01-15       Impact factor: 22.113

8.  Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.

Authors:  Jessica L Teeling; Ruth R French; Mark S Cragg; Jeroen van den Brakel; Marielle Pluyter; Haichun Huang; Claude Chan; Paul W H I Parren; C Erik Hack; Michael Dechant; Thomas Valerius; Jan G J van de Winkel; Martin J Glennie
Journal:  Blood       Date:  2004-06-01       Impact factor: 22.113

9.  Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas.

Authors:  O W Press; F Appelbaum; J A Ledbetter; P J Martin; J Zarling; P Kidd; E D Thomas
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

10.  Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.

Authors:  J K Bubien; L J Zhou; P D Bell; R A Frizzell; T F Tedder
Journal:  J Cell Biol       Date:  1993-06       Impact factor: 10.539
View more
  17 in total

Review 1.  Development trends for human monoclonal antibody therapeutics.

Authors:  Aaron L Nelson; Eugen Dhimolea; Janice M Reichert
Journal:  Nat Rev Drug Discov       Date:  2010-09-03       Impact factor: 84.694

Review 2.  Monoclonal antibodies in treatment of multiple sclerosis.

Authors:  P S Rommer; A Dudesek; O Stüve; U K Zettl
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 3.  Protein engineering to target complement evasion in cancer.

Authors:  Darrick Carter; André Lieber
Journal:  FEBS Lett       Date:  2013-11-14       Impact factor: 4.124

4.  Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.

Authors:  David T Rodgers; Magdalena Mazagova; Eric N Hampton; Yu Cao; Nitya S Ramadoss; Ian R Hardy; Andrew Schulman; Juanjuan Du; Feng Wang; Oded Singer; Jennifer Ma; Vanessa Nunez; Jiayin Shen; Ashley K Woods; Timothy M Wright; Peter G Schultz; Chan Hyuk Kim; Travis S Young
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-12       Impact factor: 11.205

5.  Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.

Authors:  Zhao Hui Li; Qian Zhang; Hai Bin Wang; Ya Nan Zhang; Ding Ding; Li Qiang Pan; David Miao; Shi Xu; Chen Zhang; Pei Hua Luo; Hua Naranmandura; Shu Qing Chen
Journal:  Invest New Drugs       Date:  2013-08-01       Impact factor: 3.850

Review 6.  Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.

Authors:  Stefan Bittner; Tobias Ruck; Heinz Wiendl; Oliver M Grauer; Sven G Meuth
Journal:  Ther Adv Neurol Disord       Date:  2016-09-02       Impact factor: 6.570

Review 7.  CD19 as a molecular target in CNS autoimmunity.

Authors:  Olaf Stüve; Clemens Warnke; Krystin Deason; Martin Stangel; Bernd C Kieseier; Hans-Peter Hartung; Hans-Christian von Büdingen; Diego Centonze; Thomas G Forsthuber; Volker Knappertz
Journal:  Acta Neuropathol       Date:  2014-07-04       Impact factor: 17.088

8.  Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.

Authors:  Marina Vivarelli; Manuela Colucci; Alice Bonanni; Martina Verzani; Jessica Serafinelli; Francesco Emma; Gianmarco Ghiggeri
Journal:  Pediatr Nephrol       Date:  2016-09-29       Impact factor: 3.714

9.  Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells.

Authors:  Susanne Hörl; Zoltan Banki; Georg Huber; Asim Ejaz; Brigitte Müllauer; Ella Willenbacher; Michael Steurer; Heribert Stoiber
Journal:  Haematologica       Date:  2013-07-12       Impact factor: 9.941

10.  Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others.

Authors:  Hideaki Kobayashi; Yuka Matsunaga; Yumiko Uchiyama; Kenji Nagura; Yasuhiko Komatsu
Journal:  Cancer Med       Date:  2013-02-20       Impact factor: 4.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.